

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32344A  
APPLICATION NO.  
10/505,399  
APPLICANT  
AVRAMIS ET AL.  
FILING DATE  
AUGUST 19, 2004

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Ottaviani et al., "Simultaneous in vitro exposure to Glivec (formerly STI571), Apo2L/TRAIL and Interferon-alpha, with or without prior Ara-C treatment, Apo2L/TRAIL-induced cytotoxicity and apoptosis in BCR/ABL + leukemic blasts," Blood, Vol. 98(11), Part 2, pp. 265b-266b (2001)
	AS	Marley et al., "Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia," British Journal of Haematology 2002, Vol. 116(1), pp. 162-165 (2002)
	AT	"Chronic Myelogenous Leukemia and Investigational Treatment Strategies," Leukemia Insights, Online!, Vol. 6(3), pp. 1-8 (2001)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32344A  
APPLICATION NO.  
10/505,399  
APPLICANT  
AVRAMIS ET AL.  
FILING DATE  
AUGUST 19, 2004

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Topaly et al., "Synergistic activity of STI571 with chemotherapeutic drugs and irradiation," Blood, Vol. 96(11), Part 1, p. 736a (2000)
DB	Druker Brian J et al., "A phase I study of Gleevec (imatinib mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia positive chronic myeloid leukemia (CML)," Blood, Vol. 98(11), Part 1, pp. 845A-846A (2001)
DC	Ruchatz et al., "Co-administration of STI571 and idarubicin increases the sensitivity to cytotoxic treatment in vitro and in vivo," Blood, Vol. 98(11), Part 1, pp. 101a-102a (2001)
DD	Keating, "Leukemia: a model for drug development," Clinical Cancer Research, The American Association for Cancer Research, US, Vol. 3(12), Part 2, pp. 2598-2604 (1997)
DE	Berman et al., "Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia," Blood, Vol. 77(8), p. 1666-1674 (1991)
DF	Rosee La et al., "Insights from pre-clinical studies for new combination treatment regimens with the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective," Leukemia, Vol. 16(7), pp. 1213-1219 (2002)
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.